Abstract: Candidemia is frequent in critically ill patients, especially in combination with an acute kidney injury (AKI). Echinocandins generally are recommended for therapy of such infections. Recent studies found no need for dosage adjustment in patients with end-stage renal disease receiving hemodialysis, or patients with AKI receiving continuous venovenous hemofiltration. The aim of this in vitro study was to examine the adsorption of anidulafungin to the surface of the hemofilter during continuous venovenous hemodialysis (CVVHD) and its effect on anidulafungin concentrations. The concentration of anidulafungin in the dialyzed fluid, and the dialysate during CVVHD in vitro was examined using three different dialyzed fluids (saline; saline with 40 g/L human albumin; and a mixture of human erythrocytes and fresh frozen plasma).
After the end of dialysis, the hemofilter was opened and portions of the filter capillaries were also analyzed to determine the amount of anidulafungin adsorbed. When dialyzing saline, about 99% of the anidulafungin used adsorbed to the hemofilter capillaries; in the experiments with saline with 40 g/L albumin, about 60% adsorbed to the hemofilter's surface, and when blood was dialyzed, 35% was found adsorbed after analyzing the filter capillaries. Anidulafungin was not detectable in the dialysate of any of the experiments, consequently the dialysis clearance was 0 mL/min. In conclusion, during CVVHD in vitro we found remarkable adsorption of anidulafungin to the hemofilter's surface, yet the effect on the tissue concentration needs further examination. Key Words: Renal replacement therapy-Echinocandins-Artificial membranes.
Acute kidney injury (AKI) is a frequent complication in critically ill patients, which occurs in nearly every third admission to an intensive care unit (ICU), and the incidence has greatly increased in recent years (1) . The rate of hospitalization for AKI in US hospitals in 1980 was 1.8/10 000 and increased to 36.5/10 000 in 2005 (2) . Candidemia is a frequent reason for bloodstream infections, particularly in ICUs (3) . In surgical ICUs in the United States, 9.82 Candida bloodstream infections per 1000 admissions were reported, whereas patients with AKI had a fourfold increased risk in comparison to patients without this diagnosis (3) . These facts show that both antifungal drugs and continuous renal replacement therapy are widely used in ICUs. Consequently, the pharmacokinetic characteristics of an antifungal drug during renal replacement therapy are of great importance for numerous patients.
Especially in critically ill patients, an echinocandin is generally recommended for therapy of Candidemia, except for Candida parapsilosis infections (4, 5) . This recommendation is emphasized by the fact that a recent study found no evidence for emerging resistance against echinocandins among invasive Candida isolates (6) . Anidulafungin is the newest agent in the group of echinocandins (7, 8) . It is, as all echinocandins, fungicidal against most Candida spp. (6, (8) (9) (10) and also shows high fungistatic efficacy against many Aspergillus species (8,10,11).
Due to poor oral bioavailability, which is typical for echinocandins (8) , anidulafungin has to be administered intravenously. After intravenous administration, anidulafungin has a predictable pharmacokinetic profile, including dose-proportional plasma concentrations (12) . It has a volume of distribution of about 33 L at steady state, which is achieved after a loading dose (double the daily dose) and one normal dose (12) . The protein binding of anidulafungin is >99% (13). Anidulafungin is a large lipopeptide molecule with a molecular weight of 1140.3 Da (13) . As all echinocandins it is an amphiphilic hexapeptide with an N-linked acyl lipid side-chain, in the case of anidulafungin consisting of a lipophilic alkoxytriphenyl (terphenyl) sidechain (8) .
Anidulafungin does not undergo hepatic metabolization or renal excretion, but is degraded nonenzymatically and eliminated in the feces (14) . Therefore, the clearance of anidulafungin is approximately 1 L/h, regardless of hepatic or renal insufficiency (15) .
In contrast, drug dosing under renal replacement therapy is quite difficult since it is subject to many factors (16, 17) . For example, variable amounts of the drugs might adsorb to a hemofilter's surface (18) (19) (20) (21) (22) . Dowell et al. (15) showed that the anidulafungin blood concentration is not affected by hemodialysis in patients with end-stage renal disease, and Leitner et al. (23) confirmed that no dosage adjustment is necessary in patients receiving continuous venovenous hemofiltration (CVVHF). In addition, the studies of Aguilar et al. (24) and Burkhardt et al. (25) found no need for dosage adjustment in patients receiving continuous venovenous hemodiafiltration (CVVHDF) and extended daily dialysis (EDD).
The aim of this study was to analyse the effect of continuous renal replacement therapy (continuous venovenous hemodialysis, CVVHD) on anidulafungin concentrations due to adsorption to the surface of the hemofilter. For this investigation, the results of different compositions of dialyzed solutions were examined.
MATERIALS AND METHODS

In vitro CVVHD system
A 2 L glass bottle was used as a reservoir for the in vitro dialysis. Three different solutions were used ( Fig. 1) : First, 1650 mL of normal saline. Second, albuminous saline, consisting of 1250 mL of normal saline and 400 mL of 20% human albumin (80 g of albumin in total, Baxter, Vienna, Austria) to give a total volume of 1650 mL. Third, a mixture of 600 mL of human erythrocytes, 400 mL of fresh frozen plasma (FFP), 100 mL of 8.4% NaHCO 3 and 10 000 IU heparin (2 mL), of which 1000 mL were used (pH 7.13 6 0.03 [SD], hematocrit 34.5 6 2.12, about 29 g of plasma proteins in total, based on a typical concentration of 80 g/L of the FFP (26)) in substitution for 1 L of fresh human blood. To calculate the dilution volume of the tube system and hemofilter, we weighed the system before and after flushing it with saline, which showed a total volume of 350 mL. We considered this volume in our calculations, as we included it in the total volume of 1350 mL in the experiments with human blood and 2000 mL in the experiments with pure saline/albuminous saline, respectively. An overview of the experiments is shown in Table 1 . The total albumin concentration in the experiments with albuminous saline was 40 g/L. In the experiments with blood the total protein concentration was approx. 21.5 g/L. During all experiments, a magnetic stirrer was used to continuously mix the solutions. Dialysis was performed with an Edwards bm11a/bm14 dialysis system (Edwards Lifesciences Germany GmbH, Unterschleissheim, Germany). SH 27 Solution (B. Braun, Melsungen, Germany) was used as dialysate and the hemofilters were Fresenius Ultraflux AV 600S (Fresenius Polysulfone, surface area 1.4 m 2 , Fresenius Medical Care, Bad Homburg, Germany). All experiments were done in duplicate.
High-performance liquid chromatography
A modified method for detecting anidulafungin in plasma, saline and dialysate was used according to Dowell et al. (15) . The high-performance liquid chromatography (HPLC) was an Agilent 1200 Series HPLC system with an Agilent 1200 Series fluorescence detector working at 225 nm excitation, and 431 and 300 nm emission wavelengths for anidulafungin and internal standard laudanosine (Aldrich, Milwaukee, WI, USA), respectively. A binary gradient (solvent A: 10 mM KH 2 PO 4 [Fluka, Buchs, Switzerland], pH 4.5; solvent B: acetonitrile [HPLC Gradient Grade, Roth, Karlsruhe, Germany]) was used to separate the target substances on a Silice Upti-prep Strategy 100A 2.2 mm PRO column (Interchim, Montluc¸on, France) equipped with a 4 3 2 mm C18 pre-column (Phenomenex, Aschaffenburg, Germany). The gradient started at a flow rate of 0.4 mL/min with 5% solvent B. It changed linearly to 90% B at 10 min and then back to 5% B at 12 min. The total run time was 15 min. The retention time for anidulafungin and laudanosine was 9.9 and 6.8 min, respectively.
For every sample, 100 mL of saline, plasma or dialysate was treated with 5 mL (0.069 mg) of internal standard laudanosine, then 250 mL acetonitrile/ 10 mM KH 2 PO 4 buffer (10/90, vol/vol) was added. This mixture was applied to a 130-mg SPE column (Bond Elut-Certify, 130 mg, 1 mL, part number 12102083, Varian, Darmstadt, Germany), which was preconditioned with 1 mL of acetonitrile/ 10 mM KH 2 PO 4 buffer (10/90, vol/vol). Afterwards, the SPE column was washed with 500 mL of acetonitrile/10 mM KH 2 PO 4 buffer (10/90, vol/vol), followed by 500 mL of chloroform (Fluka). Anidulafungin and laudanosine were eluted with 2 mL of acetonitrile/10 mM KH 2 PO 4 buffer (70/30, vol/vol) and collected in conical glass tubes. After evaporation at 408C, the residue was resolved in 50 mL of acetonitrile/10 mM KH 2 PO 4 buffer (50/50, vol/vol) and transferred into 300 mL micro vial inserts (Klaus Trott Chromatographie-Zubeh€ or, Kriftel, Germany). Five microliters were injected into the HPLC. In the autosampler the extracts were cooled to 88C until analysis. The matrix-free limit of detection was 8 ng/mL, the matrix-free limit of quantification was 32 ng/mL and the correlation coefficient was >0.999. Inter-and intra-day variability were 23.7 and 14.6%, respectively.
Experiments
The experiments were started with anidulafungin concentrations similar to typical peak plasma concentrations (15) . After the start of dialysis, anidulafungin was added as shown in Table 2 , to substitute for any potential losses to the hemofilter or the dialysate. The resulting anidulafungin concentrations are shown in Fig. 2 .
Dialysis conditions were as follows: duration of dialysis: 375 min, blood flow rate: 200 mL/min and dialysate flow rate: 800 mL/h. Ultrafiltration was set to zero. Samples from the arterial und venous line (approx. 2 mL) were collected at the start of dialysis, and then every 15 min until the end of the experiment at 375 min. The arterial samples at 0 min were taken directly from the reservoir to establish baseline data before the first pass of the hemofilter, accepting a slightly higher concentration in these samples since the reservoir had not yet been mixed with the normal saline in the tube system. Dialysate samples were collected at 60, 120, 180, 240, 300, 330, and 360 min. Blood samples were centrifuged (Heraeus Biofuge pico, 5 min at 10 000 g, Heraeus, Osterode, Germany) and then stored at 2208C; all other samples were also stored at 2208C after collection. After dialysis, the hemofilter was opened by cutting away the ends with potting compound. Remaining fluids inside the filter were discarded. The capillaries were then removed from the housing and weighed. The arithmetic mean weight of the capillaries of all the filters examined was 127.1 6 13.7 g. The bundle of capillaries was spread on a flat surface and five 1 g samples consisting of complete capillaries (i.e., from the inlet to the outlet) were collected from evenly distributed portions to represent the whole filter and to prevent distortion due to preferential adsorption that might occur at certain parts of the filter. Each of these samples was put into 10 mL of 10 mM KH 2 PO 4 buffer solution, stored in an ultrasound bath for 10 min, and samples from the buffer solution were analyzed. Then the procedure was repeated with fresh buffer solution and finally 10 mL of acetonitrile/10 mM KH 2 PO 4 buffer (50/50, vol/ vol) were used to extract the remaining anidulafungin from the hemofilter capillaries. 
Calculations
RESULTS
Normal saline
After the beginning of dialysis, the anidulafungin concentration of the dialyzed saline dropped to 0.02 mg/mL within 1 h (arithmetic mean of all arterial and venous samples, taken after 60 min of dialysis; Fig. 3 ; theoretical concentration of anidulafungin at that time: 3 mg/mL; Fig. 2 ). Also after each administration of anidulafungin, the measured concentrations dropped within 1 h to 0.04 mg/mL (theoretical concentration 5 mg/mL) and 0.08 mg/mL (theoretical concentration 7.5 mg/ mL) after 120 and 180 min, respectively. After the last administration of anidulafungin (after 3 h of dialysis, theoretical concentration 10 mg/mL), the measured concentration dropped to 0.16 mg/mL within 1 h and decreased further until the end of the experiment (after 375 min of dialysis), at which the concentration was 0.04 mg/mL. Thus, in the examined range of concentrations of up to 10 mg/ mL anidulafungin (Fig. 2) , there was nearly no anidulafungin left in the dialyzed fluid after 1 h. Due to the absence of anidulafungin in the dialysate, the hemofilters were opened after each experiment as described earlier. In the analysis of the hemofilters, we found no detectable anidulafungin in the washing fluid after washing the filter capillaries in 10 mM KH 2 PO 4 buffer. But after edulcorating them with acetonitrile/10 mM KH 2 PO 4 buffer (50/ 50, vol/vol), anidulafungin concentrations of 164.5 6 11.7 mg/g could be found in the filter capillaries. Taking into account the weight of the hemofilter capillaries and the fact that 20 mg of anidulafungin were used during each experiment, about 98.5 6 7% of the anidulafungin was bound to the hemofilter in these experiments.
Albuminous saline
In the experiments with albuminous saline, higher concentrations of anidulafungin were achieved in the dialyzed fluid. After the beginning of dialysis, the anidulafungin concentration dropped continuously to 1.52 mg/mL after 1 h ( Fig.  4 ; theoretical concentration 3 mg/mL). After 120 and 180 min of dialysis, the measured values for anidulafungin in the dialyzed fluid were 1.48 mg/mL (theoretical concentration 5 mg/mL) and 2.78 mg/ mL (theoretical concentration 7.5 mg/mL), respectively. After the last administration of anidulafungin after 3 h of dialysis (theoretical concentration 10 mg/mL), the anidulafungin concentration in the dialyzed fluid dropped to 3.73 mg/mL and 1.75 mg/ mL at 240 and 375 min, respectively.
After washing the hemofilter capillaries with acetonitrile/10 mM KH 2 PO 4 buffer (50/50, vol/vol), anidulafungin concentrations of 103.1 6 44.1 mg/g in the filter capillaries could be found. Extrapolating this value to the weight of the examined hemofilter capillaries results in an anidulafungin binding rate of 60.3 6 25.8% of the 20 mg used, explaining the decline in the measured anidulafungin concentrations in the dialyzed fluids.
Blood
In the experiments with blood, the measured anidulafungin concentrations in the dialyzed fluids were closest to the expected concentrations. The adsorbed amount of anidulafungin was the lowest of all performed experiments. After 1 h of dialysis, the anidulafungin concentration in the dialyzed fluid was 1.26 mg/mL ( Fig. 5 ; theoretical concentration 2.22 mg/mL). After 120 and 180 min of dialysis, the measured values for anidulafungin in the dialyzed fluid were 2.06 mg/mL (theoretical concentration 3.70 mg/mL) and 4.66 mg/mL (theoretical concentration 7.41 mg/mL), respectively. After 240 min of dialysis (theoretical concentration 11.11 mg/ mL), the measured anidulafungin concentration was 5.16 mg/mL and 60 min after the last administration of anidulafungin (after 300 min of dialysis, theoretical concentration 14.81 mg/mL), the measured anidulafungin concentration was 11.49 mg/mL and dropped to 8.99 mg/mL at the end of the experiment after 375 min of dialysis. In particular in this experiment the dispersion of the measured anidulafungin concentrations after the last administration of anidulafungin (after 240 min) was higher compared to the experiments with lower concentrations (saline and albuminous saline). A drug accumulation in the system in the experiments with higher concentrations, might explain this finding. The samples from the washing fluid that were taken after washing the filter capillaries with acetonitrile/ 10 mM KH 2 PO 4 buffer (50/50, vol/vol) showed anidulafungin concentrations of 48.7 6 13.3 mg/g in the filter capillaries. This finding indicates that 35.3 6 9.6% of the total 20 mg anidulafungin administered adsorbed to the filter surface.
Consistent with the findings of other authors for different renal replacement methods (15, (23) (24) (25) , no anidulafungin was detectable in the dialysate of any of the experiments performed, thus the dialysis clearance was 0 mL/min.
DISCUSSION
The main finding in our study was that about 35% of anidulafungin adsorbs to the hemofilter surface when dialyzing blood. Consistent with the findings of other authors (15, (23) (24) (25) anidulafungin was not dialyzable.
Correct drug dosing is crucial, especially in critically ill patients, and this is sometimes difficult in patients receiving renal replacement therapy since it is often influenced by many factors (16, 17) . For example, the concentration of a drug may be influenced by the hemofilter due to adsorption to the filter surface (18) (19) (20) (21) (22) . Thus, the aim of our in vitro study was to assess the amount of anidulafungin adsorbing to the synthetic surface of a hemofilter during CVVHD.
The proposed dosage regimen for anidulafungin is 100 mg/day, after a 200 mg loading dose on Day 1 for patients with candidemia and other Candida infections, such as intra-abdominal abscess or peritonitis (13) . Administered this way, a C max of 8.6 mg/mL and an AUC of 111.8 mgÁh/L is achieved in healthy adults, and similar values are seen in patients with fungal infections (13) . Patients suffering from esophageal candidiasis should be treated with 100 mg of anidulafungin on Day 1, followed by a maintenance dose of 50 mg/day (13) . Following this dosage regimen, anidulafungin concentrations between 1.6 and 4.2 mg/mL are achieved in patients with fungal infections (13) . The minimum inhibitory concentration of anidulafungin required to inhibit the growth of at least 90% of isolates (MIC 90 ) was 2 mg/L and the MIC 50 was 0.06 mg/L in 5346 tested isolates of Candida spp. (6) . For Aspergillus fumigatus, the median minimum effective concentration (MEC) is reported to be 0.12 mg/L, for Aspergillus terreus and Aspergillus flavus, the MEC is 0.25 mg/L (27) .
Anidulafungin is extensively bound to plasma proteins (>99%) (13) and shows considerably increased MICs in the presence of serum (28) (29) (30) . The effect of the presence of serum on anidulafungin, or rather all echinocandins, is also confirmed by the fact that the echinocandins show considerably different MICs and MECs for Candida spp. and Aspergillus spp., respectively, in vitro, whereas they adapt to each other in the presence of serum and in vivo, and show comparable MICs and MECs under these conditions (30) . It is not clear whether this effect derives from protein-bound anidulafungin being inactive with only a small amount of free drug left over for antimicrobial activity, or if anidulafungin is still active when bound to serum proteins (30) . Dowell et al. (15) found that no dosage adjustment is necessary in patients undergoing hemodialysis. In contrast, we found the anidulafungin concentration to be considerably altered in our in vitro dialysis experiments. On the one hand, this shows that the effect in vivo may be less relevant, which is also supported by the findings of other authors (23) (24) (25) . On the other hand, however, it could also be that there is a possibility that renal replacement therapy affects a parallel anidulafungin therapy, consistent with the findings of Leitner et al. (23) who concluded a loss of anidulafungin due to adherence to synthetic surfaces when using a polyethersulfone hemofilter for CVVHF. Aguilar et al. (24) used a polysulphone hemofilter for CVVHDF and found no adherence to synthetic surfaces and assumed that the findings of Leitner et al. (23) might be explained by different plasma collection methods (24) . In the study of Burkhardt et al. (25) , a polysulphone hemofilter was used for EDD and no adherence to the filter membrane was reported.
We found the adsorbed amount of administered anidulafungin to be 35% when dialyzing blood. If about 35% of the anidulafungin adsorbed to a hemofilter, this would indicate that the resulting plasma concentration in patients who are treated with 100 mg anidulafungin per day would still be above the required concentration to treat most Candida infections. However, in patients who receive 50 mg anidulafungin per day, a reduction of 35% in anidulafungin plasma concentration could result in concentrations below the desired level, especially when infections with Candida spp., which require higher anidulafungin concentrations, like C. parapsilosis (MIC 90 : 2 mg/L (6,31)), are present. Although echinocandins are not recommended as the first-line therapy for C. parapsilosis infections (5).
Most pharmacokinetic data focus on the total concentration of a drug. According to our data, the hemofilter seems to particularly influence the free anidulafungin concentration with the adsorbed amount of anidulafungin being 35 and 99% when dialyzing blood and saline, respectively. Anidulafungin's chemical structure with three linear arranged aromatic rings indicates that a strong interaction with a linear polyaromatic synthetic surface, such as a polysulfone hemofilter, without sterical hindrance is most likely. A reduction in the adsorption of anidulafungin to the filter surface in the presence of albumin or blood because of a blocking of the filter surface by proteins is less probable due to low albumin adhesion to the polysulfone surface (32) .
The fact that, in our experiments, the presence of human plasma-in contrast to saline and albuminresulted in a lower adsorption to the hemofilter might be explained by a larger amount of anidulafungin being protein-bound in these experiments. The reason for this might either be the fact that anidulafungin is not only bound to albumin, but also to other serum components, or a different binding potency of albumin in the presence of serum. Both theories were introduced by Zeitlinger et al. (33) when examining the effect of protein binding on fluoroquinolones.
Consequently, the effect on patients receiving both renal replacement therapy and anidulafungin might exceed the expected effect from the sole reduction of the total anidulafungin concentration due to the primary decrease of free anidulafungin. There are no specific studies on the tissue distribution of anidulafungin in humans, but in animal studies anidulafungin was quickly distributed into tissues most commonly affected by fungal infections (34) . Consequently, a parallel renal replacement therapy might have a greater effect on the anidulafungin concentration in these key organs. Based on this, it might be reasonable to perform further studies to investigate the effect of renal replacement therapies on the antifungal efficacy of anidulafungin in vivo, as this may have more clinical relevance than total plasma concentrations. Microdialysis experiments in intensive care patients could investigate the influence of CVVHD on anidulafungin penetration in tissues (35) .
Another aspect that should be further evaluated is the fact that critically ill patients are often malnourished. In these patients, the effect of reduced serum proteins could yield higher concentrations of free drug (36) , but simultaneous renal replacement therapy could lead to a higher amount of drug adsorbing to the hemofilter. The fact that this was an in vitro study, and only one type of hemofilter was examined are potential limitations of the present study. Further studies to evaluate other types of hemofilters are necessary, since the type of membrane can have a major influence on the adsorption of various drugs (20) . In addition, the length of time a hemofilter has been exposed to a particular substance may also influence its effect on the substance's concentration (22) . Another critical point is that we only examined anidulafungin adsorption during CVVHD. Since the findings of other authors indicated no need for dosage adjustment during other renal replacement methods (23-25), we did not investigate these in the present study. However, further studies to examine their effect on the adsorption of anidulafungin to the hemofilter membrane seem warranted.
CONCLUSION
In conclusion, this in vitro study showed that about 35% of the anidulafungin administered can adsorb to a hemofilter, but still the blood concentration seems to remain above the level required to fight most Candida and Aspergillus infections (6, 27, 31) . However, most data focus on total drug concentrations and there is only little information available on the biologically active concentration of anidulafungin and the tissue distribution in humans. Therefore, it is not clear to what extent a hemofilter influences the active amount of anidulafungin, and whether the necessary drug concentration can be reached at the site of infection.
